Jerome Stevens' $1.3 Bil. Levothyroxine Suit Against FDA Dismissed
This article was originally published in The Pink Sheet Daily
Executive Summary
D.C. federal court rules that FDA acted within its authority to extend the deadline to review levothyroxine products. Damage from FDA's release of confidential information related to Jerome Stevens' Unithroid NDA was not demonstrated to be separate from that of the deadline extension.